Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 14.3 USD 3.62% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Intellia Therapeutics Inc?
Write Note

EV/FCFF
Enterprise Value to FCFF

-1.9
Current
-6.4
Median
3.6
Industry
Higher than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-1.9
=
Enterprise Value
714.5m USD
/
FCFF
-382.7m USD
All Countries
Close
 
US
Intellia Therapeutics Inc
NASDAQ:NTLA
Average EV/FCFF: 30.6
Negative Multiple: -1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -238 717.7
US
Abbvie Inc
NYSE:ABBV
23.3
US
Amgen Inc
NASDAQ:AMGN
32.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -80.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -469.9
AU
CSL Ltd
ASX:CSL
64.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.2

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More